GRACE

Real-World Experience Study of an Active Drug For the Treatment of Endometriosis in Canada

Brief summary

The objective of this study is to evaluate real-world effectiveness of an active drug in Canadian women with endometriosis.

Interventional study

Status:
Recruiting
Conditions:
Endometriosis
Enrollment:
400 patients
Protocol ID:
P19-933
Observational model:
Cohort
Time perspective:
Prospective

Would you like to know more about this trial?

Yes, please contact me

Eligibility criteria

Participant attributes:
Female

Age:

From 18 Years to 50 Years.

Inclusion Criteria:

- Prescribed elagolix as part of standard treatment

- Naive to elagolix prior to starting this study or have stopped taking elagolix for 2
months prior to the start of this study

- Symptomatic endometriosis (clinically or surgically diagnosed) including currently
experiencing dysmenorrhea

- Has provided written informed consent allowing the use of their data for the study

Exclusion Criteria:

- Did not consent

- Cannot fill out questionnaires

- Prescribed elagolix for a period of 1 or 2 months only

- Post-menopausal (naturally or surgically)

- Symptomatic uterine fibroid(s)

- Had medical treatment for uterine fibroids (any length of treatment)

All the cities where the clinical studies are located

Calgary - T2E 7W7

Calgary - T3M 1M4

Edmonton - T5T 1L6

Vancouver - V6H 2N9

St. John's - A1A 4Y3

Halifax - B3K 6R8

Hamilton - L8S 4K1

London - N5X 2N7

Ottawa - K1H 8L6

Sudbury - P3E 5M4

Toronto - M4N 3M5

Toronto - M5B 1W8

Toronto - M5G 1X5

Gatineau - J8P 7H2

Lasalle - H8N 1T9

Longueuil - J4N 1C2

Montreal - H3T 1E2

Montréal - H1T 2M4

Montréal - H4A 3T2

Québec - G1V 4G2

Regina - S4S 6X3

British Columbia

Newfoundland and Labrador

Nova Scotia

Saskatchewan